Establishment Labs (NASDAQ:ESTA) Shares Gap Up - Still a Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report)'s stock price gapped up before the market opened on Thursday . The stock had previously closed at $36.06, but opened at $38.00. Establishment Labs shares last traded at $38.09, with a volume of 113,380 shares changing hands.

Analyst Ratings Changes

Separately, Stephens reaffirmed an "overweight" rating and set a $52.00 price objective on shares of Establishment Labs in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $57.40.

Establishment Labs Trading Up 0.0 %

The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -16.62 and a beta of 1.12. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The company's 50 day simple moving average is $37.50 and its two-hundred day simple moving average is $41.34.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The business had revenue of $44.51 million for the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. Research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ESTA. Toronto Dominion Bank acquired a new position in Establishment Labs in the 4th quarter valued at $24,879,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Establishment Labs by 15.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock worth $2,196,000 after purchasing an additional 6,307 shares during the last quarter. Union Square Park Capital Management LLC boosted its position in shares of Establishment Labs by 47.0% during the 4th quarter. Union Square Park Capital Management LLC now owns 160,000 shares of the company's stock valued at $7,371,000 after acquiring an additional 51,192 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Establishment Labs by 650.0% during the 4th quarter. Vestal Point Capital LP now owns 300,000 shares of the company's stock valued at $13,821,000 after acquiring an additional 260,000 shares in the last quarter. Finally, Stonepine Capital Management LLC boosted its position in shares of Establishment Labs by 6.7% during the 4th quarter. Stonepine Capital Management LLC now owns 80,002 shares of the company's stock valued at $3,686,000 after acquiring an additional 5,002 shares in the last quarter. Institutional investors own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.